The expression of hormonal receptors in the tumor cells further supported the breast origin and provided potential therapeutic targets, highlighting the value of comprehensive IHC evaluation in cases of metastatic disease with an unknown primary origin. This evidence concerns the gene NR4A1 and neoplasm.